SILVER SPRING
Tremfya label expanded for joint damage prevention
- Sponsor
- Johnson & Johnson $JNJ
- Drug
- Tremfya · guselkumab
- Indication
- joint damage prevention
FDA approved a supplemental BLA for Tremfya to include evidence supporting its efficacy in preventing further joint damage.
Read original at drugs.com ↗Drug Watch — recent news on Tremfya
- Q&A: Why APEX May Not Prove Guselkumab is Superior for PsA Joints - HCPLive
- Dupixent, Skyrizi, Tremfya, Keytruda, Darzalex, and - GlobeNewswire
- Choosing the Right IL-23 Treatment for Psoriatic Disease - HCPLive
- Can Tremfya Cause Erectile Dysfunction? - View roUUXbGlS - akhmetovfoundation.org
- Risk of Paradoxical Hidradenitis Suppurativa in Psoriasis Varies by Biologic Agent - medpagetoday.com
Sponsor Watch — recent news on Johnson & Johnson
- PepsiCo (PEP) Adds A New Director, Is The Discount To Fair Value Warranted?
- The S&P 500 Has Returned About 11% Annually Since 1958. Here's the ETF I'd Trust for the Next 30 Years.
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
- Johnson & Johnson (JNJ) Faces A Fresh Valuation Test On DePuy Sale Talk
- Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?